🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

Jeremy Grantham’s NBIX Holdings & Trades

First Buy
Q4 2025
Duration Held
3 Quarters
Largest Add
Q2 2026
+36,804 Shares
Current Position
72,430 Shares
$12.21 M Value

Jeremy Grantham's NBIX Position Overview

Jeremy Grantham (via Grantham, Mayo, Van Otterloo & Co. LLC) currently holds 72,430 shares of Neurocrine Biosciences, Inc. (NBIX) worth $12.21 M, representing 0.03% of the portfolio. First purchased in 2025-Q4, this short-term holding has been held for 3 quarters.

Based on 13F filings, Jeremy Grantham has maintained this position in NBIX for several quarters, showing initial confidence in the investment. Largest addition occurred in Q2 2026, adding 36,804 shares.

Analysis based on 13F filings available since 2013 Q2

Jeremy Grantham's Neurocrine Biosciences (NBIX) Holding Value Over Time

Track share changes against reported price movement

Quarterly Neurocrine Biosciences (NBIX) Trades by Jeremy Grantham

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q2 2026 +36,804 Add 103.31% 72,430 $168.53
Q1 2026 +28,493 Add 399.45% 35,626 $131.74
Q4 2025 +7,133 New Buy 7,133 $141.83

Jeremy Grantham's Neurocrine Biosciences Investment FAQs

Jeremy Grantham first purchased Neurocrine Biosciences, Inc. (NBIX) in Q4 2025, acquiring 7,133 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Jeremy Grantham has held Neurocrine Biosciences, Inc. (NBIX) for 3 quarters since Q4 2025.

Jeremy Grantham's largest addition to Neurocrine Biosciences, Inc. (NBIX) was in Q2 2026, adding 72,430 shares worth $12.21 M.

According to the latest 13F filing for Q2 2026, Jeremy Grantham's firm, Grantham, Mayo, Van Otterloo & Co. LLC, owns 72,430 shares of Neurocrine Biosciences, Inc. (NBIX), valued at approximately $12.21 M.

As of the Q2 2026 filing, Neurocrine Biosciences, Inc. (NBIX) represents approximately 0.03% of Jeremy Grantham's publicly disclosed stock portfolio, making it one of their key holdings.

Jeremy Grantham's peak holding in Neurocrine Biosciences, Inc. (NBIX) was 72,430 shares, as reported at the end of Q2 2026.